An observational study in Dactinomycin Adverse Reaction and Bone and Joint Infection, sponsored by Hospices Civils de Lyon. Status unknown at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-05-06.
Sponsored by Hospices Civils de Lyon · Observational
the aim of this study is to investigate the relationship between exposure to daptomycin and the occurrence of muscle toxicity or eosinophilic pneumonia in patients treated with daptomycin for bone and joint infection
Daptomycin is widely used in osteoarticular infections (IOA), as an alternative to vancomycin, and recommended for this use by various learned societies including the Infectious Diseases Society of America (IDSA) in 2013.
Tolerance to daptomycin is generally favorable, with in particular better renal tolerance than vancomycin. However, two rare and potentially severe side effects have been described with this antibiotics: muscle toxicity and eosinophilic pneumonia.
6,687 studies on the registry are indexed under Infections; 807 are open to participants now.
This study's planned enrollment of 1,130 is above the median of 240 across 2,136 observational studies indexed under Infections.
Browse Infections studies →Hospices Civils de Lyon is the lead sponsor of 1,826 studies on the registry; 439 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Patients managed at the CRIOAc Lyon who have had an osteoarticular infection, treated with daptomycin, with at least one blood test for daptomycin performed
Exclusion Criteria:
patients having an osteoarticular infection treated with daptomycin and which developped eosinophilic pneumonia or elevation of CPK
Other: patients having had BJI or PJI treated with daptomycin
patients having had BJI or PJI treated with daptomycin who developped an adverse event : eosinophilic pneumonia and/or elevation of CPK
rate of patients having had a PJI or BJI treated by daptomycin
proportion of patients treated by daptomycin
Time frame: between 2010 and 2020
description of BJI/PJI
type of BJI or PJI
Time frame: between 2010 and 2020
description of patients
comorbidites
Time frame: between 2010 and 2020
description of adverse event
type of adverse event
Time frame: between 2010 and 2020
rate of patients having had an adverse event
proportion of patients having had an adverse event under daptomycin
Time frame: between 2010 and 2020
Evalutation of the adverse event due to daptomycin : dosage of daptomycine
description of the use of daptomycine : dosage
Time frame: between 2010 and 2020
Evalutation of the adverse event due to daptomycin : duration of daptomycine
description of the use of daptomycine : duration
Time frame: between 2010 and 2020
Evalutation of the adverse event due to daptomycin : daptomycine plasma clearance
mean daptomycine plasma clearance (unit, liters per hour)
Time frame: between 2010 and 2020
Evalutation of the adverse event due to daptomycin : daptomycine volume distribution
mean daptomycine volume of distribution (unit, liters)
Time frame: between 2010 and 2020
Plan to share: Undecided
This study is status unknown, as verified in May 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Hospices Civils de Lyon